Nicoya Life

Nicoya Lifesciences develops label-free biophysical characterization instruments that enable researchers to measure protein binding, structure, stability, and kinetics across the drug discovery and development workflow. The company's product portfolio spans three categories: binding kinetics (Revo, a next-generation digital SPR platform; Alto, the world's first digital SPR system; OpenSPR; and SX20 stopped-flow), stability and structure (SUPR-DSF differential scanning fluorimetry and Chirascan circular dichroism), and structural dynamics (FastHDX, a millisecond hydrogen-deuterium exchange mass spectrometry platform). Nicoya's instruments are designed to reduce barriers to high-quality data through automated workflows, low sample consumption, and reproducible publication-quality results. The integrated portfolio supports confident decisions from discovery through development, serving discovery and optimization, mechanism of action characterization, and stability and quality applications. The company is trusted by top pharmaceutical companies and leading academic institutions worldwide. Founded in 2012 and headquartered in Kitchener, Canada, Nicoya Lifesciences has raised $35 million in a Series A round backed by the Golden Triangle Angel Network, MaRS IAF, Maple Leaf Angels, Innovation Grade Ventures, BDC Capital, University of Waterloo, and Waterloo Alumni Angels.